Table 1.
Characteristics of RCTs that used HIPEC in patients with ovarian cancer
| Author | Year of publication | Recruitment period | HIPEC group (n) | Control group (n) | Experimental arm |
Control arm | Median follow-up (months) | Median OS (months) |
Median PFS (months) |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HIPEC drug | Duration (min) | Temp (°C) | Chemotherapy | H | C | H | C | |||||||
| Primary ovarian cancer | ||||||||||||||
| Lim (NACT)22 | 2022 | 2010-2016 | 34 | 43 | Cisplatin 75 mg/m2 | 90 | 41.5 | Carboplatin and paclitaxel (+NACT) | Carboplatin and paclitaxel (+NACT) | 69.4 | 61.8/48.2 | 17.4/15.4 | ||
| Lim22 | 2022 | 2010-2016 | 58 | 49 | Cisplatin 75 mg/m2 | 90 | 41.5 | Carboplatin and paclitaxel | Carboplatin and paclitaxel | 69.4 | 71.3/— | 23.9/29.7 | ||
| Campos23 | 2022 | 2012-2018 | 35 | 36 | Cisplatin 75 mg/m2 | 60 | 42-43 | Carboplatin and paclitaxel (+NACT) | Carboplatin and paclitaxel (+NACT) | 32 | 52/45 | 18/12 | ||
| Van Driel25 | 2018 | 2007-2016 | 122 | 123 | Cisplatin 100 mg/m2 | 90 | 40 | Carboplatin and paclitaxel (+NACT) | Carboplatin and paclitaxel (+NACT) | 56.4 | 45.7/33.9 | 14.2/10.7 | ||
| Diaz-Montes27 | 2018 | 2014-2018 | 10 | 9 | Carboplatin 800 mg/m2 | 90 | — | Carboplatin and paclitaxel | I.V. paclitaxel/i.p. cisplatin/i.p. paclitaxel | — | — | — | ||
| Recurrent ovarian cancer | ||||||||||||||
| Zivanovic24 | 2021 | 2014-2019 | 49 | 49 | Carboplatin 800 mg/m2 | 90 | 41-43 | Carboplatin and paclitaxel or gemcitabine or doxorubicin | Carboplatin and paclitaxel or gemcitabine or doxorubicin | 39.5 | 52.5/59.7 | 12.3/15.7 | ||
| Spiliotis26 | 2014 | 2006-2013 | 60 | 60 | Cisplatin 100 mg/m2 and paclitaxel 175 mg/m2 or doxorubicin 35 mg/m2 and (paclitaxel 175 mg/m2 or mitomycin 15 mg/m2) | 60 | 42.5 | Systemic chemotherapy | Systemic chemotherapy | — | 26.7/13.4 (mean) | — | ||
C, control group; H, HIPEC group; HIPEC, hyperthermic intraperitoneal chemotherapy; NACT, neoadjuvant chemotherapy; OS, overall survival; PFS, progression-free survival; RCTs, randomized controlled trials.